Equillium Stock News

Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi

Equillium Inc (EQ) said it had begun a Phase 3 trial of its drug, itolizumab, in patients with acute graft-versus-host disease (aGVHD). aGVHD is an inflammatory response by the…

Equillium Inc (NASDAQ: EQ ), with only one asset in its pipeline , is expanding its drug development efforts via the acquisition of Bioniz Therapeutics . The deal, worth approximately $330 million, gives the biotech access to three therapeutics. Equillium will buy Bioniz in an all-stock deal for around 5.69 million shares and up to $57.5 million in development biobucks. The deal … Full story available on Benzinga.com

Equillium (EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront…

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high un

Equillium Inc (EQ) shares closed today 14.1% lower than it did at the end of yesterday. The stock is currently down 4.5% year-to-date, down 28.4% over the past 12 months, and down 74.3% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 fell 0.0%. Trading Activity Shares traded as high as $4.25 and as low as $3.38 this week.Shares closed 68.2% below its 52-week high and 6.5% above its 52-week low.Trading volume this week was 52.5% lower than the 10-day average and 21.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -613.3% The company's stock price performance over the past 12 months lags the peer average by 2085.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target peak and sustained reduction of CD6

What is Equillium all about? We started the company four years ago around our lead drug program itolizumab. My colleague, Steve Connelly, who is our chief scientific officer, realized the [] The post Equillium CEO Bruce Steel: We are among the few evaluated in first-line GVHD treatment first appeared on AlphaStreet .

Equillium, Inc. (NASDAQ:EQ) Stock analysts at SVB Leerink boosted their FY2021 earnings estimates for Equillium in a research note issued on Monday, December 13th. SVB Leerink analyst T. Smith now expects that the company will post earnings per share of ($1.37) for the year, up from their previous estimate of ($1.40). SVB Leerink currently []

Equillium, Inc. (NASDAQ:EQ) – Investment analysts at SVB Leerink increased their FY2025 earnings estimates for Equillium in a research note issued to investors on Monday, December 13th. SVB Leerink analyst T. Smith now expects that the company will post earnings of $0.29 per share for the year, up from their prior forecast of $0.26. SVB […]

Equities analysts expect that Equillium, Inc. (NASDAQ:EQ) will report earnings of ($0.34) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Equilliums earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.24). Equillium reported earnings per share of ($0.36) during []

Goldman Sachs Group Inc. acquired a new stake in Equillium, Inc. (NASDAQ:EQ) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 218,162 shares of the companys stock, valued at approximately $1,285,000. Goldman Sachs Group Inc. owned 0.74% of Equillium as of its most []

Equillium (NASDAQ:EQ) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations. Analyst Ratings This is a summary of recent ratings and price targets for Equillium and Histogen, as []